Volition: Edison Open House Healthcare 2022

Volition: Edison Open House Healthcare 2022

VolitionRx Limited manufactures epigenetic cancer detection blood tests. The Company’s tests are designed to detect the nucleosome patterns that are specific to cancer in the blood and identify some of the major nucleosome varieties that differ between cancer types.

• Please provide a summary of nucleosomes.
• Please explain how you look for disease through supplementary information found in the nucleosomes?
• How will Volition commercialise this platform?
• What kind of disease is detected? Is it in humans and dogs?
• Is this process used for screening or diagnosis?
• In 2021, you made the shift from an R&D-focused company to a commercial company. How have you added to your team to support this?
• Please tell us about your Nu.Q. platform.
• Are you continuing to run R&D alongside your commercialisation work?
• What are your key priorities for 2022?


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.